CN-121991187-A - ACT structural domain protein from shigella dysenteriae and application thereof in preparation of anti-tumor and anti-radiation medicines

Abstract

The invention relates to the technical field of biological medicine, in particular to ACT structural domain protein from shigella dysenteriae and application thereof in preparing anti-tumor and anti-radiation medicines. The invention provides an ACT structural domain protein, the amino acid sequence of which is shown as SEQ ID NO. 2. The ACT structural domain protein provided by the invention is used as a functional protein derived from intestinal probiotics, and provides a novel molecular probe and a research object for revealing the action mechanism of intestinal flora in tumorigenesis and development. The protein not only provides an entry point for researching intestinal microecology and tumor immunity interaction, but also lays a foundation for developing novel biomarkers and drug targets based on microbiome, and has important scientific value in the fields of tumor biology and microorganism-host interaction research.

Inventors

• YANG JING
• PAN YUCHEN
• CHENG YU
• JIANG RUIHAN

Assignees

• 徐州医科大学

Dates

Publication Date

20260508

Application Date

20260213

Claims (9)

1. 1. The ACT domain protein is characterized in that the amino acid sequence is shown in SEQ ID NO. 2.
2. 2. A nucleic acid molecule encoding the ACT domain protein of claim 1, wherein the nucleotide sequence is set forth in SEQ ID No. 1.
3. 3. Use of the ACT domain protein of claim 1 in the manufacture of a medicament for the treatment of cancer.
4. 4. The use according to claim 3, wherein the ACT domain protein ACTs by targeted inhibition of the mitochondrial glutamate transporter SLC25a 22.
5. 5. The use according to claim 3, wherein the cancer is rectal cancer.
6. 6. Use of the ACT domain protein of claim 1 in the manufacture of a medicament for enhancing an anti-tumor immune response in a host.
7. 7. Use of the ACT domain protein of claim 1 for the preparation of a medicament for the prevention and treatment of ionizing radiation damage.
8. 8. Use of the ACT domain protein of claim 1 in the manufacture of a medicament for the treatment of an organ transplant immune related disorder.
9. 9. A pharmaceutical composition comprising the ACT domain protein of claim 1 and a pharmaceutically acceptable carrier.

Description

ACT structural domain protein from shigella dysenteriae and application thereof in preparation of anti-tumor and anti-radiation medicines Technical Field The invention relates to the technical field of biological medicine, in particular to ACT structural domain protein from shigella dysenteriae and application thereof in preparing anti-tumor and anti-radiation medicines. Background Clinical treatment of tumors, particularly solid tumors such as colorectal cancer, presents the dual challenges of limited response rate and high drug resistance of existing therapies. Colorectal cancer is taken as an example, and the morbidity and mortality of colorectal cancer respectively lodge in the prostate of malignant tumors, and the patient population shows a tendency to younger. Although surgery, chemoradiotherapy, targeting and immunotherapy constitute the current major therapeutic systems, most advanced patients eventually develop drug resistance or intolerance to these therapies, leading to disease progression, which highlights the urgent need for new anti-tumor strategies with new mechanisms of action that can overcome the limitations of existing therapies. The limitations of existing therapies have prompted the exploration of new targets and new molecules against tumors. In recent years, the interaction of intestinal microecology with tumors has become a research hotspot, and probiotics have been found to potentially enhance the effects of chemotherapy or immunotherapy by modulating tumor immune microenvironment and the like. However, the direct application of live bacteria preparations to tumor treatment has significant obstacles that the colonization efficiency of strains in complex human intestinal tracts is unstable, potential transformation safety risks (such as infection caused by flora translocation) exist, and the baseline difference of intestinal flora among individuals is huge, so that the curative effect is difficult to predict and standardize. These fundamental deficiencies severely hamper the shift of probiotic therapy from basic research to stable, controlled clinical. Thus, the research perspective is moving from intact viable bacteria to specific effector molecules that function. One key strategy is to directly identify and exploit functional molecules (e.g., secreted proteins, metabolites) secreted or released by probiotics that have direct biological activity, bypassing the uncertainty of viable bacterial use. The molecules are used as an 'executor' of the probiotics function, possibly have the advantages of clear ingredients, clear action mechanism, more controllable pharmacokinetics and the like, and provide a more ideal starting point for developing novel medicines. In summary, the key active molecules capable of directly inhibiting tumor growth or regulating anti-tumor immunity are systematically screened and identified from probiotics, and the precise molecular targets and action mechanisms of the key active molecules are clarified, so that the key active molecules are not only important for deeply understanding the scientific principle of microorganism-host interaction in tumor treatment, but also the necessary way for converting the research result of intestinal flora into innovative biological agents or treatment strategies which are high-efficiency, low-toxicity and capable of accurately administering the next generation. Disclosure of Invention In order to solve the problems in the prior art, the invention provides the application of ACT domain protein from shigella dysenteriae in preparing a preparation for resisting cancer, targeted inhibiting mitochondrial glutamate transporter SLC25A22, enhancing host anti-tumor immune response and preventing and treating ionizing radiation injury, and the application of ACT domain protein in preparing medicines for researching and/or treating tumors such as CRC, radioactive diseases and organ transplantation immunity. In order to achieve the above object, the present invention provides the following technical solutions: The invention provides an ACT structural domain protein, the amino acid sequence of which is shown as SEQ ID NO. 2. The invention provides a nucleic acid molecule for encoding the ACT structural domain protein, and the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID NO. 1. The invention provides application of the ACT structural domain protein in preparing medicaments for treating cancers. Preferably, the ACT domain protein functions by targeted inhibition of the mitochondrial glutamate transporter SLC25a 22. Preferably, the cancer is rectal cancer. The invention provides application of the ACT structural domain protein in preparing a medicine for enhancing host anti-tumor immune response. The invention provides application of the ACT structural domain protein in preparing medicines for preventing and treating ionizing radiation injury. The invention provides application of the ACT structural domain protein in pre